RYSTIGGO: source applicability and renal evidence limits
An explicit no-adjustment instruction and a limited supporting study range can coexist. Preserve both; do not label an unstudied dialysis regimen as clinically validated.
Before applying: Subcutaneous infusion only; use the labeled weight-based regimen.
Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Rxlist source
RYSTIGGO: selected RX renal passage
Product / population
Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal measure
Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source revision
Revision date not established in reviewed mirror passage.
Retrieved
2026-11-07 (not the revision date)
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Evidence is population PK, not a dedicated severe-renal or dialysis study.
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
Section 12.3, Patients with Renal Impairment
The mirror includes the no-adjustment instruction and a population-PK range of eGFR 38-161 mL/min/1.73 m2. A dedicated renal study was not conducted.
Source revision: Revision date not established in reviewed mirror passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
RYSTIGGO: selected primary-label renal guidance and limits
Source retrieved 2026-11-07 - confirm current applicability
No dialysis regimen established in selected content
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
RYSTIGGO: source applicability and renal evidence limits
An explicit no-adjustment instruction and a limited supporting study range can coexist. Preserve both; do not label an unstudied dialysis regimen as clinically validated.
How to use this: Subcutaneous infusion only; use the labeled weight-based regimen.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
RYSTIGGO: selected primary-label renal guidance and limits
Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
An RX mirror and its underlying label are not independent clinical confirmations.
DailyMed / product prescribing information · Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2 Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Evidence is population PK, not a dedicated severe-renal or dialysis study.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 12.3, Patients with Renal Impairment
The label states no dose adjustment is required with renal impairment. No dedicated renal PK study was performed; population data included mild/moderate impairment, with eGFR 38-161 mL/min/1.73 m2. This explicit instruction is retained without claiming that severe impairment or dialysis was directly validated.
RDM72-rozanolixizumab-rystiggo-label-1 · Source locator: Section 12.3, Patients with Renal Impairment
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
GlobalRPh RX List / label mirror · Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2 Source date: Revision date not established in reviewed mirror passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Evidence is population PK, not a dedicated severe-renal or dialysis study.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 12.3, Patients with Renal Impairment
The mirror includes the no-adjustment instruction and a population-PK range of eGFR 38-161 mL/min/1.73 m2. A dedicated renal study was not conducted.
RDM72-rozanolixizumab-rystiggo-rx-1 · Source locator: Section 12.3, Patients with Renal Impairment
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
